Hematologic Malignancy
Lymphoid Neoplasm
CI-CAN-00009335Explore in graph →
Hematologic2,419 active trials60 approved drugs271 evidence items
- OncoTree
- LNM
Loading cancer entity…
Loading cancer entity…
Hematologic Malignancy
CI-CAN-00009335Explore in graph →
Clinical trials
8,886 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (1,374)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT00749502 | A Study of MK4827 in Participants With Advanced Solid Tumors or Hematologic Malignancies (MK-4827-001 AM8) | completed | Phase 1 | 113 | Tesaro, Inc.INDUSTRY | 0 | Jul 25, 2013 | clinicaltrials |
| NCT00842595 | Efficacy , Safety of Treatment R NIMP for Relapsed Aggressive Lymphomas | completed | Phase 2 | 50 | French Innovative Leukemia OrganisationOTHER | 1 | Jul 24, 2013 | clinicaltrials |
| NCT00723359 | Safety and Dose Determining Study of BT062 in Patients With Relapsed or Refractory Multiple Myeloma | completed | Phase 1 | 32 | Biotest Pharmaceuticals CorporationINDUSTRY | 1 | Jul 18, 2013 | clinicaltrials |
| NCT01060202 | Quality of Life of Non-transplant Candidate Multiple Myeloma Patients Treated With Early Bortezomib | completed | — | 60 | Janssen Korea, Ltd., KoreaINDUSTRY | 0 | Jul 17, 2013 | clinicaltrials |
| NCT00089154 | Apolizumab in Treating Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma | completed | Phase 2 | 32 | National Cancer Institute (NCI)NIH | 1 | Jul 16, 2013 | clinicaltrials |
| NCT00697671 | Pilot Study of Haploidentical Natural Killer Cell Infusions for Poor Prognosis Non-AML Hematologic Malignancies | completed | Phase 1 | 48 | St. Jude Children's Research HospitalOTHER | 1 | Jul 16, 2013 | clinicaltrials |
| NCT01402687 | SNP-Based Prediction of Oral Mucositis Risk in Patients Receiving Hematopoietic Stem Cell Transplants (HSCT) | completed | — | 181 | Dana-Farber Cancer InstituteOTHER | 1 | Jul 16, 2013 | clinicaltrials |
| NCT00871702 | Infusion of Genetically Modified T Cell for Post Transplant Patients With Relapsed Disease | completed | Phase 1 | 12 | Washington University School of MedicineOTHER | 1 | Jul 11, 2013 | clinicaltrials |
| NCT01440556 | Allogeneic Bone Marrow Transplantation From Unrelated Donors in Multiple Myeloma(MM2011) | completed | — | 196 | Azienda Ospedaliera San Giovanni BattistaOTHER | 1 | Jul 11, 2013 | clinicaltrials |
| NCT01118845 | Study of SyB L-0501 in Combination With Rituximab to Treat Relapsed/Refractory Diffuse Large B-Cell Lymphoma | completed | Phase 2 | 63 | SymBio PharmaceuticalsINDUSTRY | 2 | Jul 4, 2013 | clinicaltrials |
| NCT01371227 | A Study of JNS002 (Doxorubicin Hydrochloride Liposome Injection) in Relapsed or Refractory Multiple Myeloma | completed | Phase 1 | 3 | Janssen Pharmaceutical K.K.INDUSTRY | 1 | Jul 4, 2013 | clinicaltrials |
| NCT00685997 | Whole-body Magnetic Resonance Imaging (MRI) for Staging Malignant Lymphomas | completed | — | 135 | UMC UtrechtOTHER | 1 | Jul 3, 2013 | clinicaltrials |
| NCT00002970 | 506U78 in Treating Patients With Refractory Hematologic Cancer | completed | Phase 2 | 148 | National Cancer Institute (NCI)NIH | 1 | Jul 2, 2013 | clinicaltrials |
| NCT00012181 | Flavopiridol in Treating Children With Relapsed or Refractory Solid Tumors or Lymphomas | completed | Phase 1 | 30 | National Cancer Institute (NCI)NIH | 1 | Jul 2, 2013 | clinicaltrials |
| NCT00352846 | Effect of Zoledronic Acid on Chemotherapy Induced Bone Loss | completed | Phase 3 | 135 | M.D. Anderson Cancer CenterOTHER | 1 | Jul 2, 2013 | clinicaltrials |
| NCT00807677 | A Phase 1 Dose Escalation Study of TAK-901 in Subjects With Advanced Hematologic Malignancies | completed | Phase 1 | 31 | Millennium Pharmaceuticals, Inc.INDUSTRY | 1 | Jul 2, 2013 | clinicaltrials |
| NCT00994500 | Vorinostat and Bortezomib in Treating Young Patients With Refractory or Recurrent Solid Tumors, Including Central Nervous System Tumors and Lymphoma | completed | Phase 1 | 20 | National Cancer Institute (NCI)NIH | 1 | Jul 2, 2013 | clinicaltrials |
| NCT00969462 | Doxorubicin Pharmacokinetics and Response in Non Hodgkin's Lymphoma | completed | Phase 4 | 18 | Meir Medical CenterOTHER | 1 | Jul 1, 2013 | clinicaltrials |
| NCT01221571 | A Study to Assess AFM13 in Patients With Hodgkin Lymphoma | completed | Phase 1 | 28 | Affimed GmbHINDUSTRY | 2 | Jun 26, 2013 | clinicaltrials |
| NCT00090493 | Study of MAGE-A3 and NY-ESO-1 Immunotherapy in Combo With DTPACE Chemo and Auto Transplantation in Multiple Myeloma | completed | Phase 2 / Phase 3 | 4 | University of ArkansasOTHER | 1 | Jun 24, 2013 | clinicaltrials |
| NCT01149668 | A Safety and Tolerability Study of PCI-24781 in Subjects With Cancer | completed | Phase 1 | 7 | Pharmacyclics LLC.INDUSTRY | 1 | Jun 19, 2013 | clinicaltrials |
| NCT01271127 | Screening for Coronary Artery Disease After Mediastinal Irradiation(SCAR) | completed | N/A | 50 | Leiden University Medical CenterOTHER | 1 | Jun 12, 2013 | clinicaltrials |
| NCT00010192 | Rituximab Plus Interleukin-2 in Treating Patients With Hematologic Cancer | completed | Phase 1 | 30 | National Cancer Institute (NCI)NIH | 1 | Jun 6, 2013 | clinicaltrials |
| NCT00101270 | Oxaliplatin and Irinotecan in Treating Young Patients With Refractory Solid Tumors or Lymphomas | completed | Phase 1 | 24 | National Cancer Institute (NCI)NIH | 1 | Jun 5, 2013 | clinicaltrials |
| NCT00017472 | Monoclonal Antibody Therapy in Treating Patients With Chronic Lymphocytic Leukemia, Lymphocytic Lymphoma, Acute Lymphoblastic Leukemia, or Acute Myeloid Leukemia | completed | Phase 1 | 35 | National Cancer Institute (NCI)NIH | 1 | Jun 4, 2013 | clinicaltrials |
| NCT00058227 | Alvocidib, Fludarabine Phosphate, and Rituximab in Treating Patients With Lymphoproliferative Disorders or Mantle Cell Lymphoma | completed | Phase 1 | 37 | National Cancer Institute (NCI)NIH | 1 | Jun 4, 2013 | clinicaltrials |
| NCT00062244 | Oblimersen in Treating Patients With Relapsed or Refractory Waldenstrom's Macroglobulinemia | completed | Phase 1 / Phase 2 | 58 | National Cancer Institute (NCI)NIH | 1 | Jun 4, 2013 | clinicaltrials |
| NCT00109824 | Decitabine With or Without Valproic Acid in Treating Patients With Relapsed or Refractory Non-Hodgkin's Lymphoma | completed | Phase 1 | 42 | National Cancer Institute (NCI)NIH | 1 | Jun 4, 2013 | clinicaltrials |
| NCT00002556 | Combination Chemotherapy With or Without High Dose Cyclophosphamide and Recombinant Interferon Alfa-2b in Treating Patients With Previously Untreated Stage I-III Multiple Myeloma | completed | Phase 3 | 312 | National Cancer Institute (NCI)NIH | 1 | May 31, 2013 | clinicaltrials |
| NCT00926757 | Prophylactic Use of Entecavir for Non-Hodgkin's Lymphoma Patients With Resolved Hepatitis B(HBVNHL) | completed | Phase 4 | 80 | Taipei Veterans General Hospital, TaiwanOTHER_GOV | 1 | May 29, 2013 | clinicaltrials |
| NCT00873457 | Perifosine in Relapsed or Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma | completed | Phase 2 | 16 | Daphne FriedmanOTHER | 1 | May 27, 2013 | clinicaltrials |
| NCT00944905 | Study of MDX-1203 in Subjects With Advanced/Recurrent Clear Cell Renal Cell Carcinoma (ccRCC) or Relapsed/Refractory B-Cell Non-Hodgkin's Lymphoma (B-NHL) | completed | Phase 1 | 46 | Bristol-Myers SquibbINDUSTRY | 1 | May 22, 2013 | clinicaltrials |
| NCT00054483 | Bortezomib in Treating Patients With Advanced Cancer and Kidney Dysfunction | completed | Phase 1 | 69 | National Cancer Institute (NCI)NIH | 1 | May 16, 2013 | clinicaltrials |
| NCT01801436 | A Post-Approval Pharmacokinetic Study of Bortezomib in Participants With Multiple Myeloma | completed | Phase 3 | 14 | Johnson & Johnson Taiwan LtdINDUSTRY | 0 | May 16, 2013 | clinicaltrials |
| NCT00348985 | PXD101 and Bortezomib in Treating Patients With Advanced Solid Tumors or Lymphomas | completed | Phase 1 | 55 | National Cancer Institute (NCI)NIH | 1 | May 3, 2013 | clinicaltrials |
| NCT01292486 | Evaluation of the Spectra Optia® Mononuclear Cell Collection Procedure | completed | N/A | 32 | Terumo BCTINDUSTRY | 1 | May 1, 2013 | clinicaltrials |
| NCT00715208 | Phase 2 Study of VELCADE (Bortezomib) in Patients With Relapsed Follicular Lymphoma | completed | Phase 2 | 55 | Millennium Pharmaceuticals, Inc.INDUSTRY | 2 | Apr 29, 2013 | clinicaltrials |
| NCT00346255 | BB-10901 in Treating Patients With Relapsed and/or Refractory Multiple Myeloma(IMGN901) | completed | Phase 1 | 37 | ImmunoGen, Inc.INDUSTRY | 2 | Apr 23, 2013 | clinicaltrials |
| NCT00545519 | A Phase I Study Of Thymoglobulin In Patients With Relapsed Or Refractory Multiple Myeloma | completed | Phase 1 | 6 | Washington University School of MedicineOTHER | 1 | Apr 23, 2013 | clinicaltrials |
| NCT01268774 | Preventive Treatment of VETD in Patients With Multiple Myeloma Receiving Chemotherapy With Thalidomide or Lenalinomide. | completed | — | 529 | LEO PharmaINDUSTRY | 0 | Apr 18, 2013 | clinicaltrials |
| NCT00440635 | Expanded Access Protocol (EAP) to Provide Bortezomib to Patients With Multiple Myeloma Who Have Received at Least 2 Previous Lines of Therapy and Are Refractory to or Have Relapsed After Their Last Therapy for Multiple Myeloma | completed | — | 641 | Janssen-Cilag International NVINDUSTRY | 0 | Apr 16, 2013 | clinicaltrials |
| NCT01829412 | Whole Body Diffusion Weighted Magnetic Resonance Imaging (DW-MRI) in Multiple Myeloma(MMY-MRI-08) | completed | N/A | 50 | Fondazione IRCCS Istituto Nazionale dei Tumori, MilanoOTHER | 0 | Apr 11, 2013 | clinicaltrials |
| NCT00002563 | SWOG-9208 Quality of Life and Health Status in Patients With Stage I or Stage II Hodgkin's Disease | completed | — | 263 | SWOG Cancer Research NetworkNETWORK | 1 | Apr 10, 2013 | clinicaltrials |
| NCT00060372 | Ipilimumab After Allogeneic Stem Cell Transplant in Treating Patients With Persistent or Progressive Cancer | completed | Phase 1 | 21 | National Cancer Institute (NCI)NIH | 1 | Mar 27, 2013 | clinicaltrials |
| NCT01188798 | Methotrexate or Pentostatin for Graft-versus-host Disease Prophylaxis in Risk-adapted Allogeneic Bone Marrow Transplantation for Hematologic Malignancies | completed | Phase 3 | 6 | St. Jude Children's Research HospitalOTHER | 1 | Mar 21, 2013 | clinicaltrials |
| NCT00303797 | Sorafenib and Bortezomib in Treating Patients With Advanced Cancer | completed | Phase 1 | 50 | National Cancer Institute (NCI)NIH | 1 | Mar 19, 2013 | clinicaltrials |
| NCT00996957 | Study of ACE-041 in Patients With Advanced Solid Tumors or Relapsed/Refractory Multiple Myeloma | completed | Phase 1 | 37 | Acceleron Pharma, Inc., a wholly-owned subsidiary of Merck & Co., Inc., Rahway, NJ USAINDUSTRY | 1 | Mar 18, 2013 | clinicaltrials |
| NCT01025206 | A Study of a Human Anti-Intercellular Adhesion Molecule-1 Monoclonal Antibody, in Patients With Multiple Myeloma | completed | Phase 1 | 35 | BioInvent International ABINDUSTRY | 4 | Mar 15, 2013 | clinicaltrials |
| NCT01148108 | Study of Canfosfamide in Refractory or Relapsed Mantle Cell, Diffuse Large B Cell Lymphoma and Multiple Myeloma | completed | Phase 2 | 14 | TelikINDUSTRY | 1 | Mar 15, 2013 | clinicaltrials |
| NCT01536145 | CP-751,871 Treatment For Patients With Multiple Myeloma | completed | Phase 1 | 47 | PfizerINDUSTRY | 1 | Mar 15, 2013 | clinicaltrials |
Data updated 23 days agoSource updated Jul 25, 2013source: clinicaltrials